Natera

Update in progress

NTRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Natera is a diagnostics company developing and marketing molecular tests worldwide. Its portfolio includes Signatera (ctDNA MRD and treatment monitoring), Latitude (colorectal MRD), Altera (tissue genomic profiling), Empower (hereditary cancer screening), Panorama (noninvasive prenatal testing), Horizon (carrier screening), Fetal Focus sgNIPT, Vistara (single-gene NIPT), Anora (miscarriage tissue analysis), Prospera (organ transplant monitoring), Renasight (kidney gene panel), Constellation (cloud distribution), and NateraCore with phlebotomy and EMR integration. It partners with BGI Genomics and was founded in 2003 in Austin, TX.

Company score

Sentiment: 0.17; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive